As with antiretroviral combinations used in treatment, passive immunization of broadly neutralizing antibodies for prevention may require two or more bNAbs that target different parts of the virus. This graphic outlines the bNAb combinations being explored in early clinical studies.
Broadly Neutralizing Antibody Combinations
Biomedical HIV Prevention Trials: Results, milestones and more
This graphic shows the updated status of large-scale prevention trials through 2022 and the impact of COVID-19 on each trial.
Another version of this graphic is available here (same content, different visual Treatment U=U).
COVID-19 Vaccine Pipeline PowerPoint Presentation
This set of slides offers advocates a view of the funders, platforms, research phase and considerations for some of the front-runner candidates.
A Global Pandemic Requires an Unprecedented Response
Meeting the ambitious timelines for a COVID-19 vaccine will require an unprecedented multi-faceted, coordinated global response including governments, industry, academic researchers, delivery partners, donors and civil society. This graphic represents the pillars of this landscape — with those organizations mentioned by name representing just a small fraction of the growing number of contributors in the global response to the COVID-19 pandemic.
Excerpted from Five “P”s to Watch.
The Race for a Coronavirus Vaccine
This graphic compares a conventional timeline for vaccine development, anticipating a COVID-19 vaccine available by May 2036, versus the accelerated goal of developing, producing and distributing a vaccine much, much faster. Excerpted from Five “P”s to Watch.
COVID-19 Vaccine Pipeline Snapshot
A snapshot of the COVID-19 vaccine pipeline. Excerpted from Five “P”s to Watch.
Vaccines Approaches in COVID-19 Vaccine Development
HIV represents one of the most challenging viruses ever encountered. Though an HIV vaccine has yet to be licensed, vaccine science has made enormous strides as it confronts this rapidly-mutating virus. Years of painstaking work to develop vaccines for HIV are now making possible the record-breaking timelines that researchers aspire to for the development of COVID-19 vaccines. Vaccines research has generated more scientific knowledge about immune function and responses than ever existed. And key vaccine platforms are fast-tracking the development and testing of experimental vaccines for COVID-19 today.
Excerpted from Five “P”s to Watch.
A Global Pandemic Requires an Unprecedented Response
Will compressed and overlapping steps get a vaccine faster? The innovations advocated for in Vaccines development that are being employed in the COVID-19 response today include: running certain clinical trials in parallel instead of sequentially; gearing up manufacturing capacity before final study results are in and negotiating public/private commitments in advance to facilitate sustainable access to new vaccines.
Excerpted from Five “P”s to Watch.
The Race for a Coronavirus Vaccine
Will compressed and overlapping steps get a vaccine faster? The innovations advocated for in Vaccines development that are being employed in the COVID-19 response today include: running certain clinical trials in parallel instead of sequentially; gearing up manufacturing capacity before final study results are in and negotiating public/private commitments in advance to facilitate sustainable access to new vaccines.
Excerpted from Five “P”s to Watch.
Leveraging the Vaccines Enterprise for COVID-19 Vaccine Research
In many ways, the collaborative research movement grew up around Vaccines. Thanks in large part to HIV advocacy, out-of date research models that were competitive and closed-door are increasingly yielding to more transparent and collaborative research and development efforts—in both the HIV and COVID-19 responses.
Building on big science partnerships, data sharing and collaboration pioneered over the last 15 years of Vaccines research and development, global initiatives are marshalling the talents, experiences and resources of key stakeholders. And just as HIV laid the foundation for more effective partnerships in research, lessons from the COVID-19 experience can also inspire greater collaboration and broader involvement by a range of players in the vaccines research effort.
Excerpted from 5 “P”s to Watch.